The Technical Analyst
aTyr Pharma Inc [LIFE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
aTyr Pharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.50% $1.640
America/New_York / 22 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 111.11 mill |
| EPS: | -0.940 |
| P/E: | -1.740 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 67.75 mill |
| Avg Daily Volume: | 0.555 mill |
| RATING 2024-04-22 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.740 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.30x |
| Company: PE -1.740 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.116 (-92.94%) $-1.524 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.508 - 1.772 ( +/- 8.05%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-05 | Shukla Sanjay | Buy | 10 375 | Common stock |
| 2024-02-05 | Shukla Sanjay | Sell | 10 375 | Restricted Stock Unit |
| 2024-02-05 | Broadfoot Jill Marie | Buy | 3 750 | Common stock |
| 2024-02-06 | Broadfoot Jill Marie | Sell | 1 590 | Common stock |
| 2024-02-05 | Broadfoot Jill Marie | Sell | 3 750 | Restricted Stock Unit |
| INSIDER POWER |
|---|
| 92.97 |
| Last 99 transactions |
| Buy: 4 079 228 | Sell: 350 127 |
Forecast:
16:00 - $1.630
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.630
Forecast 2: 16:00 - $1.630
Forecast 3: 16:00 - $1.630
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.640 (2.50% ) |
| Volume | 0.293 mill |
| Avg. Vol. | 0.555 mill |
| % of Avg. Vol | 52.87 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LIFE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
LIFE
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-01 08:00:00 - Press Release
Atyr Pharma To Participate In April Investor Conferences
San diego, april 01, 2024 (globe newswire) -- atyr pharma, inc. (nasdaq: life), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary trna synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in april 2024. details of the conferences appear below: conference: evercore isi diamonds in the rough webinar daydate: thursday, april 4, 2024 time: 10:30am edtlocation: virtualformat: corporate presentation with q&a session conference: piper sandler spring biopharma symposiumdate: wednesday, april 17, 2024location: everett, maformat: 1x1 investor meetings for more information on how to register, please contact your evercore isi or piper sandler representative.
2024-03-14 16:00:00 - Press Release
Atyr Pharma Announces Fourth Quarter And Full Year 2023 Results And Provides Corporate Update
Phase 3 efzo-fit™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. company launches individual patient expanded access program (eap), allowing access to efzofitimod for patients who complete efzo-fit™.
2024-02-28 08:00:00 - Press Release
Atyr Pharma To Webcast Conference Call Reporting Fourth Quarter And Full Year End 2023 Financial Results
San diego, feb. 28, 2024 (globe newswire) -- atyr pharma, inc. (nasdaq: life), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary trna synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on thursday, march 14, 2024. management will host a conference call and webcast to review the results and provide an operational update.
2024-02-21 08:00:00 - Press Release
Atyr Pharma Announces Expanded Access Program (eap) For Efzo-fit™ Clinical Trial Participants
Individual patient eap allows access to efzofitimod for patients who complete the phase 3 efzo-fit™ study in pulmonary sarcoidosis. company initiating program based on blinded efzo-fit™ study investigator and patient participant feedback.
2024-01-18 08:00:00 - Press Release
Atyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick As Advisor
Atyr pharma announces howard university president emeritus dr. wayne a. i. frederick as advisor for efzofitimod program in interstitial lung disease (ild).
Latest News
2024-04-01 08:00:00 - GlobeNewsWire
aTyr Pharma to Participate in April Investor Conferences
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024. Details of the conferences appear below: Conference: Evercore ISI Diamonds in the Rough Webinar DayDate: Thursday, April 4, 2024 Time: 10:30am EDTLocation: VirtualFormat: Corporate Presentation with Q&A Session Conference: Piper Sandler Spring Biopharma SymposiumDate: Wednesday, April 17, 2024Location: Everett, MAFormat: 1x1 Investor Meetings For more information on how to register, please contact your Evercore ISI or Piper Sandler representative.
2024-03-26 14:19:17 - InvestorPlace
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
When it comes to deciding whether you should acquire penny stocks or not, the answer is no. Okay, so we're done here, right?
2024-03-14 23:37:06 - Seeking Alpha
aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript
2024-02-28 08:00:00 - GlobeNewsWire
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update.
2024-02-15 07:49:16 - InvestorPlace
The 3 Best Penny Stocks to Buy in February 2024
Penny stocks will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecosystem of companies that make life in the financial markets, we can always identify good investment opportunities that allow us to add value to our portfolio and our wealth.
2023-11-01 08:00:00 - GlobeNewsWire
aTyr Pharma to Present at November Investor Conferences
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D.
2023-09-04 09:01:21 - Zacks Investment Research
5 Top Stocks to Play Earnings Beat Potential
These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap American Woodmark (AMWD), Skechers (SKX), Workday (WDAY), aTyr Pharma (LIFE) and Modine Manufacturing (MOD).
2023-08-30 11:16:58 - Zacks Investment Research
Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE)
Atyr Pharma (LIFE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2023-08-24 08:00:00 - GlobeNewsWire
aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Jill Broadfoot, Chief Financial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place September 11 – 13, 2023, in New York, NY.
2023-08-18 09:34:33 - Zacks Investment Research
5 Top Stocks Likely to Top Earnings Estimates
Top-ranked stocks Yum China (YUMC), Amazon.com (AMZN), Workday (WDAY), aTyr Pharma (LIFE) and D.R. Horton (DHI) are likely to beat on the bottom line in their upcoming releases.